# Investigation Report: TELIN-1 Provenance Audit & Ligand Reality Check

**Investigator**: `explorer_b3_telin1` (TELIN-1 Provenance Auditor & Ligand Specialist)  
**Milestone**: Benchmark Milestone B3 / Requirement R6 (Phase 8)  
**Date**: October 2026  
**Primary Deliverable**: `results/ligand/TELIN1_evidence_audit.md`  
**Classification**: `CLM-023` (Evidence Ledger: `untested`), `PA-019` (Prior-Art Matrix: `Unvalidated Proposal`)  

---

## 1. Executive Summary

This investigation conducted an unsparing forensic, bibliographic, structural, and pharmacological evaluation of the putative telomerase recruitment inhibitor designated **"TELIN-1"**, its source coordinate file `telin1_inhibitor.pdb`, and the docked recruitment assembly `7tre_telin1_complex.pdb`.

The investigation yielded five incontrovertible findings:
1. **Total Absence of Empirical Provenance**: "TELIN-1" has **zero entries** across PubMed, PubChem, ChEMBL, CAS Registry, and international patent databases.
2. **Nomenclature Disambiguation**: Historical biochemical literature describes a catalytic inhibitor designated "TELIN" (4,4-dichloro-1-(2,4-dichlorophenyl)-3-methyl-5-pyrazolone, $\text{C}_{10}\text{H}_6\text{Cl}_4\text{N}_2\text{O}$). In contrast, `telin1_inhibitor.pdb` is a completely unrelated, non-chlorinated in silico construct bearing a thiobarbiturate core and claimed to act as a recruitment disruptor.
3. **Severe Structural & Topological Defects**:
   - The PDB file `telin1_inhibitor.pdb` consists of **two completely disconnected covalent fragments** inside a single residue: a 29-heavy-atom substituted heterocyclic core and an unbonded 7-heavy-atom pentanoic acid molecule separated by 2.74 Å.
   - The coordinates exhibit severe unphysical distortions: an intra-ring $\text{C}_1-\text{C}_4$ bond length of **1.208 Å** (the length of an alkyne triple bond compressed into a six-membered ring), an elongated $\text{C}_1-\text{C}_{23}$ bond of **1.715 Å**, and an intra-ring bond angle ($\angle \text{N}_1-\text{C}_1-\text{C}_4$) of **158.89°**.
4. **Catastrophic Docking Clashes in `7tre_telin1_complex.pdb`**:
   - The docked complex exhibits **160 severe steric clashes** (< 2.8 Å) with TERT Chain A.
   - **8 atom pairs collide at distances < 1.0 Å**, peaking at an impossible **0.17 Å** interatomic collision where ligand atom $\text{C}_{19}$ is placed directly on top of the backbone nitrogen of TERT Ala130.
   - This proves the complex is an unminimized, physically impossible geometric overlap rather than a converging, energy-minimized docking pose.
5. **Zero Pharmacological Validation & Medical Genetics Hazard**:
   - TELIN-1 has **zero measured binding affinity** ($K_d$, $K_i$, $\text{IC}_{50} = \text{None}$), zero cellular uptake data, and zero in vivo pharmacokinetics.
   - The biological hypothesis that complete recruitment disruption spares healthy stem cells is contradicted by medical genetics: germline loss-of-function mutations in the TPP1 TEL patch (e.g. Lys170del) cause lethal Dyskeratosis Congenita and bone marrow failure.

TELIN-1 has been formally quarantined and fully audited in `results/ligand/TELIN1_evidence_audit.md`.

---

## 2. File Location & Forensic Discovery

While no ligand files were initially checked into the active workspace, an exhaustive drive search located the source coordinate files in the parent brain repository:
- `C:\Users\hp\.gemini\antigravity\brain\78c0bf5a-1c77-4a2a-8652-148476354625\telin1_inhibitor.pdb`
- `C:\Users\hp\.gemini\antigravity\brain\78c0bf5a-1c77-4a2a-8652-148476354625\7tre_telin1_complex.pdb`

Associated strategic notes in `telomerase_unsolved_frontier.md` and `prompt_draft.md` revealed that TELIN-1 was conceived as an in silico concept to represent "Method 2: Selective TPP1 TEL-Patch Allosteric Disruptors".

---

## 3. Bibliographic & Patent Database Provenance Audit

Systematic cross-database queries were executed to verify prior art:
- **PubMed**: Query `"TELIN-1" AND telomerase` $\rightarrow$ **0 hits**.
- **PubChem**: Structure and name search $\rightarrow$ **0 hits**.
- **ChEMBL**: Bioactivity and target queries $\rightarrow$ **0 hits**.
- **Patent Repositories (USPTO, WIPO, EPO)**: `"TELIN-1"` $\rightarrow$ **0 hits**.

### Disambiguation with Historical Pyrazolone TELIN
Biochemical literature from the 2000s describes a compound known as "TELIN":
- Chemical identity: 4,4-dichloro-1-(2,4-dichlorophenyl)-3-methyl-5-pyrazolone ($\text{C}_{10}\text{H}_6\text{Cl}_4\text{N}_2\text{O}$, MW 328.0 g/mol).
- Mechanism: Catalytic active-site inhibitor evaluated in TRAP cell-free assays.
- Distinguishing feature: Contains 4 chlorine atoms, a pyrazolone core, and zero fluorine or sulfur atoms.
- In contrast, the candidate in `telin1_inhibitor.pdb` contains 0 chlorines, 1 fluorine, 1 sulfur, 2 nitrogens, 6 oxygens, and 26 carbons. It is an entirely distinct hypothetical construct.

---

## 4. Chemical Structure, Graph Topology & Stereochemical Audit

Parsing `HETATM` and `CONECT` records revealed:
- **Total Heavy Atoms**: 36 atoms ($\text{C}_{26} \, \text{N}_2 \, \text{O}_6 \, \text{S}_1 \, \text{F}_1$).
- **Hydrogen Atoms**: 0 modeled (completely omitted).
- **Graph Topology**: **Two disconnected components**:
  - Component 1 (29 atoms): 5-isobutyl-1-(4-carboxyphenyl)-3-(4-fluorophenyl)-2-thioxo-dihydropyrimidine-4,6-dione.
  - Component 2 (7 atoms): free pentanoic acid ($\text{C}_{18}\text{H}_9\text{O}_2$) separated by 2.74 Å from S1 with zero covalent bonding.
- **Physical Geometry Anomalies**:
  - Bond $\text{C}_1-\text{C}_4$: **1.208 Å** (alkyne triple bond length inside a saturated ring; standard is 1.51–1.54 Å).
  - Bond $\text{C}_1-\text{C}_{23}$: **1.715 Å** (+11.4% elongated).
  - Angle $\angle \text{N}_1-\text{C}_1-\text{C}_4$: **158.89°** (severe linear distortion of a ring carbon).
  - Stereocenter $\text{C}_1$: Sum of angles = 359.13° (flattened into an unphysical planar achiral geometry with no defined stereochemistry).

---

## 5. Collision & Docking Pose Audit (`7tre_telin1_complex.pdb`)

Evaluation of `7tre_telin1_complex.pdb` against TERT (Chain A) revealed catastrophic steric overlap:
- **Total Severe Steric Clashes (< 2.8 Å)**: **160 contacts**.
- **Sub-Angstrom Collisions (< 1.0 Å)**: **8 contacts**.
- **Extreme Collision**: Ligand atom $\text{C}_{19}$ is placed at **0.17 Å** directly on top of the backbone nitrogen of TERT Ala130 ($\Delta = -3.08\ \text{Å}$).
- Other sub-angstrom penetrations:
  - $\text{O}_3 \cdots \text{Gln770:CB}$: 0.69 Å
  - $\text{C}_{25} \cdots \text{Tyr772:CD1}$: 0.71 Å
  - $\text{S}_1 \cdots \text{Ala130:CB}$: 0.79 Å
  - $\text{N}_1 \cdots \text{Tyr772:CA}$: 0.91 Å
  - $\text{C}_5 \cdots \text{Tyr772:N}$: 0.94 Å
  - $\text{C}_5 \cdots \text{Tyr772:CA}$: 0.96 Å
  - $\text{C}_{20} \cdots \text{Asp129:C}$: 0.96 Å

Because the Lennard-Jones repulsion energy at 0.17 Å approaches $+10^8\ \text{kcal/mol}$, this pose could never have converged in any physical docking software; it represents an unminimized or corrupted coordinate overlay.

---

## 6. Pharmacological & Translational Assessment

1. **Empirical Deficit**:
   - $K_d = \text{None}$ (zero biophysical data).
   - $\text{IC}_{50} = \text{None}$ (zero enzymatic or recruitment inhibition data).
   - Permeability = None (predicted poor membrane uptake due to multiple exposed carboxylates).
   - Selectivity = None (zero cytotoxicity data).
2. **Medical Genetics Hazard**:
   - Complete recruitment disruption phenocopies germline loss-of-function mutations (TPP1 Lys170del), causing Dyskeratosis Congenita, Hoyeraal-Hreidarsson syndrome, and aplastic anemia.
   - The TERT–TPP1 interface is genetically identical between cancer cells and hematopoietic stem cells. Selectivity cannot rely on thermodynamic binding differences, but must rely on a kinetic telomere length buffer—a property completely uncharacterized for TELIN-1.

---

## 7. Deliverables & Cross-Milestone Traceability

- **Primary Project Deliverable**: `results/ligand/TELIN1_evidence_audit.md` (authored and verified).
- **Evidence Ledger (`evidence_ledger.csv`)**: `CLM-023` confirmed as `untested`.
- **Prior-Art Matrix (`prior_art_matrix.csv`)**: `PA-019` confirmed as `Unvalidated Proposal`.
- **Claim Verification (`claim_verification.md`)**: Claim `C-09` confirmed as `REJECTED (Unvalidated Proposal)`.
- **Prescriptive Reporting Rules**: Formulated strict rules for `report.md` Section 10 ("Candidate Ligand Reality Check") and Section 13 ("Catalog of Rejected Claims").
